Related Experiment Video

Updated: Jun 6, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma

Hong Xu1, Irene Y Cheung, Xiao X Wei

  • 1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

International Journal of Cancer
|December 15, 2010
PubMed

Insights

Checkpoint kinase inhibitors like AZD7762 can overcome chemotherapy resistance in neuroblastoma by disrupting cell cycle checkpoints. Combining AZD7762 with DNA-damaging agents shows therapeutic potential for treating resistant neuroblastoma tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Checkpoint kinase inhibitors disrupt cell cycle checkpoints, enhancing chemotherapy efficacy.
  • Neuroblastoma often exhibits p53/MDM2/p14(ARF) genomic alterations affecting cell cycle control.
  • G(1) checkpoint defects correlate with resistance to DNA-damaging agents in neuroblastoma.

Purpose of the Study:

  • To evaluate the efficacy of AZD7762, a Chk1/2 inhibitor, in combination with DNA-damaging chemotherapy.
  • To investigate the impact of p53/MDM2/p14(ARF) status on neuroblastoma response to combination therapy.
  • To assess the in vitro and in vivo effects of AZD7762 on neuroblastoma cell cycle and tumor growth.

Main Methods:

  • Utilized neuroblastoma cell lines with defined p53/MDM2/p14(ARF) genomic status.
  • Performed in vitro cytotoxicity assays and cell cycle checkpoint analyses.
  • Conducted in vivo xenograft studies using AZD7762 and gemcitabine.

Main Results:

  • G(1) checkpoint-defective neuroblastoma lines showed resistance to DNA-damaging agents but sensitivity to AZD7762 combination therapy.
  • AZD7762 abrogated DNA damage-induced S/G(2) checkpoint arrest in vitro and in vivo.
  • Combination therapy in xenograft models significantly delayed tumor growth and increased apoptosis.

Conclusions:

  • Combination therapy with AZD7762 and chemotherapy can overcome drug resistance in neuroblastoma.
  • Targeting cell cycle checkpoints offers a promising strategy for treating neuroblastomas with defective G(1) checkpoints.
  • AZD7762 demonstrates therapeutic potential in reversing or preventing chemotherapy resistance in neuroblastoma.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...